4th Circuit En Banc Judgment Affirms District Court Decision in Best Price Stacking Case
FDA Law Blog
SEPTEMBER 30, 2022
Kirschenbaum — In November 2020, we blogged about a decision by the Federal District Court of Maryland dismissing a Federal False Claims Act (FCA) qui tam suit alleging that Forest Laboratories knowingly reported inflated best prices under the Medicaid Drug Rebate Program (MDRP), resulting in underpayment of rebates.
Let's personalize your content